- 1 Title: Real world external validation of metabolic gestational age assessment in Kenya
- 2
- 3 Steven Hawken^{1,7}
- 4 Victoria Ward²
- 5 A. Brianne Bota¹
- 6 Monica Lamoureux³
- 7 Robin Ducharme¹
- 8 Lindsav A. Wilson¹
- 9 Nancy Otieno⁴
- 10 Stephen Munga⁴
- 11 Bryan O. Nyawanda⁴
- 12 Raphael Atito⁴
- 13 Pranesh Chakraborty^{3,5}
- 14 Gary L. Darmstadt^{2*}
- 15 Kumanan Wilson^{1,6,7,8*}
- 16
- 17 ¹Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Canada
- ²Prematurity Research Center, Department of Pediatrics, Stanford University School of Medicine,
 Stanford CA, USA
- 20 ³Newborn Screening Ontario, Children's Hospital of Eastern Ontario, Ottawa, Canada
- 21 ⁴Kenya Medical Research Institute (KEMRI), Center for Global Health Research, Kisumu, Kenya
- 22 ⁵Department of Pediatrics, University of Ottawa, Ottawa, Canada
- 23 ⁶Department of Medicine, University of Ottawa, Ottawa, Canada
- 24 ⁷School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
- 25 ⁸Bruyère Research Institute, Ottawa, Canada
- 26
- 27 *Co-senior authors; these authors contributed equally to this project.
- 28 Corresponding author: Kumanan Wilson (<u>kwilson@ohri.ca</u>)
- 29
- 30

31 Keywords: gestational age algorithm, newborn screening, dried blood spots, LMIC, Kenya, KEMRI

- **33 Word Count: 2360**
- 34

32

35 Abstract

- 36
- 37 Using data from Ontario Canada, we previously developed machine learning-based algorithms 38 incorporating newborn screening metabolites to estimate gestational age (GA). The objective of this study 39 was to evaluate the use of these algorithms in a population of infants born in Siava county. Kenva. 40 Cord and heel prick samples were collected from newborns in Kenya and metabolic analysis was 41 carried out by Newborn Screening Ontario in Ottawa, Canada. Postnatal GA estimation models were 42 developed with data from Ontario with multivariable linear regression using ELASTIC NET regularization. 43 Model performance was evaluated by applying the models to the data collected from Kenva and comparing 44 model-derived estimates of GA to reference estimates from early pregnancy ultrasound. Heel prick samples were collected from 1,039 newborns from Kenya. Of these, 8.9% were born 45 46 preterm and 8.5% were small for GA. Cord blood samples were also collected from 1,012 newborns. In data 47 from heel prick samples, our best-performing model estimated GA within 9.5 days overall of reference GA 48 [mean absolute error (MAE) 1.35 (95% CI 1.27, 1.43)]. In preterm infants and those small for GA, MAE was 49 2.62 (2.28, 2.99) and 1.81 (1.57, 2.07) weeks, respectively. In data from cord blood, model accuracy slightly decreased overall (MAE 1.44 (95% CI 1.36, 1.53)). Accuracy was not impacted by maternal HIV status and 50 51 improved when the dating ultrasound occurred between 9 and 13 weeks of gestation, in both heel prick and cord blood data (overall MAE 1.04 (95% CI 0.87, 1.22) and 1.08 (95% CI 0.90, 1.27), respectively). 52 53 Compared to internal validation performance using Ontario data and to our previously published 54 external validations, model performance was diminished in the Kenva cohort, suggesting that reference 55 ultrasound timing is an important factor in model performance. Our study highlights the challenges in 56 reliably estimating GA in low resource settings, even those with access to dating ultrasound, given that the 57 timing of dating ultrasound is critical to develop algorithms for accurate estimation of GA based on 58 metabolic analysis of blood obtained at birth.
- 59
- 60
- 61
- 62

63 Introduction

64 The need for novel, non-invasive methods to accurately estimate gestational age (GA) in low resource 65 settings has been identified by the World Health Organization as a priority area for improving global 66 estimation of the burden of preterm birth at < 37 completed weeks of gestation. Preterm birth as well as 67 being born small (small for gestational age: SGA = lowest ten centiles of birthweight given gestational age) 68 are leading causes of infant mortality and morbidity, particularly in low- and middle-income countries (LMIC).^{1,2} Furthermore, medical needs and developmental milestones differ between term, preterm and SGA 69 70 infants and thus, accurately identifying at-risk infants at birth is important in informing their postnatal care 71 and supportive resources. Although the use of first-trimester ultrasound has improved our ability to estimate 72 GA³, it is not widely available in all low resource settings and its implementation poses significant obstacles, 73 including cost, training, equipment maintenance and lack of standardization.⁴ In low resource settings 74 without access to prenatal ultrasound, GA estimates are often made based on last menstrual period, the 75 accuracy of which may be affected by memory recall as well as irregular menses and maternal 76 malnutrition.^{5,6} Commonly used postnatal examination methods for GA dating of infants (e.g., Dubowitz or 77 Ballard score) also have limitations in terms of their accuracy – particularly in preterm and growth-restricted 78 infants – and their utility is further limited by challenges with feasibility and high inter-user variability.⁷ 79 80 Given the limitations associated with existing GA dating methods, numerous research groups are testing new

81 ways to accurately estimate GA.^{8–11} We have developed novel machine learning-based algorithms that use

82 newborn screening metabolites and clinical and demographic covariates to estimate GA.^{12,13} These

83 algorithms were originally developed and internally validated in a large cohort of newborns in Ontario,

84 Canada.^{14,15} Refinements to the algorithms incorporated machine learning and improved the accuracy of

gestational age estimations.^{12,16} Here we evaluate the use of these algorithms in a population of infants born
in Siaya County, Kenya.

87

88 Methods

89 *Ethics*

90 This study was approved by the Ottawa Health Sciences Network Research Ethics Board (20180330-01H),

91 Children's Hospital of Eastern Ontario Research Ethics Board (18/58X), the Stanford University School of

92 Medicine Institutional Review Board (44656) and the Kenya Medical Research Institute (KEMRI) Scientific

and Ethics Review Unit (SSC 2880).

94

95 *Study setting*

96 A detailed study protocol has previously been published which describes the study sites and provides further

97 details on sample collection and processing.¹⁷ The Kenya study site is located in Kisumu at the KEMRI

98 Centre for Global Health Research, with field sites located in Siaya County, where a maternal-infant

99 demographic surveillance program followed a prospective cohort of pregnant women and their infants in two

100 community hospitals: Siaya County Referral Hospital (SCRH) and Bondo sub-County Hospital (BSCH).

101 Eligible participants were pregnant women between the ages of 15-49 years, residing within a 10 km radius

102 of the research facility, willing to deliver in the research hospital, and not planning to relocate within 1 year

103 of enrollment into the surveillance program. Participants were enrolled at their first antenatal care visit

104 (ANC-1), which typically occurred prior to 20 weeks' gestation. Participants underwent an early pregnancy

105 ultrasound as early as possible and were offered treatment for common illnesses, including malaria, urinary

- tract infections, and sexually transmitted infections. A small portion of infants were born at home and
- evaluated within 72 hours of delivery.
- 108

109 Consent

110 Informed written parental consent was obtained prior to study enrollment. All liveborn infants of enrolled111 mothers were eligible for inclusion.

112

113 Collection of newborn screening specimens

114 Cord blood samples were collected via syringe within 30 minutes of delivery of the placenta. Four to five 115 drops of blood from the syringe were applied to filter paper within pre-printed circles. Heel prick samples 116 were collected from newborns ideally between 24-72 hours after birth, or prior to discharge if the newborn 117 was released from the hospital within 24 hours of delivery. The newborn's heel was warmed prior to skin 118 puncture to promote blood flow. The puncture site was cleaned and air-dried and a sterile lancet was used to 119 puncture the lateral plantar aspect of the newborn's heel. The first drop of blood was wiped away and 4-5 120 drops of blood were applied within pre-printed circles of a second filter paper.

121

Heel and cord dried blood spot (DBS) cards were dried and stored at ambient temperature and shipped
weekly to the Newborn Screening Ontario (NSO) laboratory at the Children's Hospital of Eastern Ontario in
Ottawa, Canada for analysis, along with clinical and demographic information required for clinical
interpretation of metabolic profiles and for metabolic GA estimation models. This information included
infant sex, birthweight (in grams), multiple birth status, GA (in weeks + days), date of birth, and timing of
sample collection.

128

129 Newborn screening analysis

130 The newborn screening analysis process has been described in detail previously.¹⁷ Dried blood spot samples

131 were analyzed for the following metabolites: hemoglobin profiles, 17-hydroxyprogesterone (17-OHP),

thyroid stimulating hormone (TSH), immunoreactive trypsinogen (IRT), a panel of 12 amino acids and

133 31 acylcarnitines, t-cell receptor excision circles (TREC), biotinidase activity, and galactose-1-

134 phosphate uridylyltransferase activity (Table 1). Real-time screening for three conditions [congenital

135 hypothyroidism (CH), hemoglobinopathies, and medium-chain acyl-CoA dehydrogenase deficiency

- 136 (MCADD)] occurred during this study. These conditions were deemed to be high priority for reporting and
- 137 were treatable at the local collection sites. Results of screening for congenital metabolic conditions will be
- 138 published elsewhere.

- 139
- 140 Data preparation and statistical analysis
- 141 All analyses were conducted using SAS 9.4 and R 3.3.2. Data preparation steps, including standardization
- 142 and log transformations are detailed in S1 Appendix.
- 143
- 144 Analytes were included as candidate predictors in GA estimation models based on their routine measurement
- as part of Ontario's expanded newborn screening program, including hemoglobin profiles, amino acids,
- 146 acylcarnitines, hormone and endocrine markers, enzymes and co-enzymes (Table 1). Newborn GA was
- 147 estimated from models derived using multivariable regression coupled with elastic net regularization and
- 148 including the following covariates:
- 149 1. Model 1: Birth weight, sex, multiple birth status and pairwise interactions.
- 150 2. Model 2: Birth weight, sex, multiple birth status and newborn screening analytes and pairwise151 interactions.
- 152

153 Table 1. Newborn screening analytes included in predictive models

Hemoglobins	Adult hemoglobin: HbA(A) Fetal hemoglobin: HbF (F), Acetylated HbF (F1)
Endocrine markers	17-hydroxyprogesterone (17-OHP), Thyroid stimulating hormone (TSH)
Amino Acids	Arginine (arg); phenylalanine (phe); alanine (ala); leucine (leu); ornithine (orn); citruline (cit); tyrosine (tyr); glycine (gly); methionine (met); valine (val);
Acyl-carnitines	C0; C2; C3; C4; C5; C5:1; C6; C8; C8:1; C10; C10:1; C12; C12:1; C14; C14:1; C14:2; C16; C18; C18:1; C18:2; C10:1; C12:1; C14:1; C14:2; C4OH; C5:1; C5DC; C5OH; C6DC; C16:OH; C16:1OH; C18OH; C18:1OH; C3DC; C4DC
Enzyme markers	Biotinidase; immunotripsinogen; galactose-1-phosphate uridylyltransferase (GALT)
T-cell Function	T-Cell Receptor Excision Circles (TREC)

154

Models were trained and internally validated in independent training and validation/test cohorts of infants 155 156 from Ontario, Canada (S1 Appendix). These pretrained models were then applied to the data for infants from 157 the external cohorts to estimate GA. To evaluate model accuracy, GA estimates were compared to the 158 ultrasound reference GA for each infant, and the residual error calculated. Different metrics were calculated 159 to estimate model uncertainty, including mean square error (MSE), standard error of estimation [also known 160 as root mean square error (RMSE)], and mean absolute error (MAE), which is the average of the absolute 161 value of the residual across all subjects (or subsets of subjects). Additionally, we calculated the proportion of 162 model-derived estimates that fell within ± 1 week of reference GA. MAE was the main performance metric 163 used to evaluate model accuracy, but multiple metrics were calculated and reported to facilitate comparisons

to other models developed by our group and others. Model-derived frequency of preterm birth will becompared to the observed prevalence of preterm birth.

- 166
- 167

168 Results

- 169 1,039 newborns had heel prick samples available, as well as clinical and demographic data including
- 170 ultrasound-derived reference GA. Of these, 92 infants (8.9%) were preterm and 88 (8.5%) were SGA (Table
- 171 2). 1,012 newborns (97.4%) also had a cord blood sample collected. It should be noted that the Ontario
- 172 cohort in which the models were developed and internally validated had a lower preterm birth prevalence of
- 173 5.6% and SGA prevalence of 3.9% (Table 2).
- 174

175 <u>Model-based GA estimation for heel prick samples</u>

- 176 Overall, Model 1, which included only readily available clinical covariates (sex, birthweight and multiple
- birth status) estimated GA within 10.5 days on average, with a MAE of 1.5 (95% CI 1.41, 1.58) weeks.
- 178 58.5% of model estimates were within ± 1 week of reference GA. For preterm births, Model 1 MAE was
- 179 2.64 (95% CI 2.30,3.01) weeks and only 24.1% of estimates were within \pm 1 week of reference GA. In SGA
- 180 newborns, MAE was 3.13 (95% CI 2.85, 3.38) weeks and 3.4% of estimates were within ± 1 week of
- 181 reference GA (Table 2). Model 2, which included clinical covariates plus analytes, estimated GA within 9.5
- days overall, with a MAE of 1.35 (95% CI 1.27, 1.43) weeks, and 64.1% of estimates were within \pm 1 week
- of reference GA. In preterm infants, MAE was 2.62 (95% CI 2.28, 2.99) weeks and in SGA infants the MAE
 was 1.81 (95% CI 1.57, 2.07) weeks (Table 3).
- 185

The performance of Models 1 and 2 did not appear to be affected by the HIV status of the mother. Results for
subjects with HIV-positive mothers (n=197) were almost identical to model performance for infants of HIVnegative mothers (n=842) (Table 4).

- 189
- 190 <u>Model-based GA estimation for cord-blood samples</u>
- 191 Model 1 demonstrated nearly identical performance in cord blood samples compared to heel prick samples,
- as analytes were not covariates in Model 1, and the heel and cord blood cohorts were almost entirely
- 193 comprised of the same infants. Overall, in the cord blood cohort, Model 2 had a MAE of 1.44 (95% CI 1.36,
- 194 1.53) weeks. In preterm infants, Model 2 had a MAE of 2.79 (95% CI 2.46, 3.12) weeks and in SGA infants
- the MAE was 2.06 (95% CI 1.76, 2.36) weeks (Table 2). Like the heel prick results, model performance was
- not sensitive to the HIV status of the mother (Table 5 and Table 6).
- 197

198 <u>Model-based GA estimation using reference GA derived from ultrasounds within recommended window</u>

199 There was significant variation in the timing of gestational dating ultrasound, despite best efforts to conduct

- the ultrasound as early as possible. Reference GA for 28 newborns (2.7%) was derived from ultrasound
- 201 conducted before 9 weeks' gestation, and 889 (85.6%) had reference GA based on an ultrasound later than

202 13 weeks' gestation. Only 120 newborns (11.5%) had reference GA based on an ultrasound conducted within

203 9-13 weeks' gestation (Table 4). When evaluated in these 120 newborns, model performance was markedly

204 better, with Model 2 having a MAE of 1.04 (95% CI 0.87, 1.22) weeks overall and a MAE of 2.56 (95% CI

205 1.50, 4.00) and 1.07 (95% CI 0.46, 1.70) weeks in preterm and SGA infants, respectively (Table 5).

206

Similar to the heel prick results, Model 2 for cord blood specimens performed markedly better when only
samples with reference GA ascertained between 9 and 13 weeks of gestation were included [overall MAE
1.08 (95% CI 0.90, 1.27) weeks] (Table 5).

210

211 Discussion

212 We externally validated the performance of a postnatal GA dating algorithm developed and validated in a 213 cohort of infants in Ontario, Canada in a prospective birth cohort in Siaya County Kenya, a lower-middle-214 income sub-Saharan African country. Heel prick and umbilical cord blood samples were collected shortly 215 after birth, and ultrasound was used to provide a reference GA for each infant. Overall, model performance 216 was worse in the Kenya birth cohort for Model 1 and Model 2 compared to internally validated model 217 performance in Ontario, and in comparison to previously published external validations of metabolic GA algorithms.^{12,13} The heterogeneity of reference ultrasound timing was an important contributor to diminished 218 219 model performance, as only 120 out of 1,039 participants had reference ultrasound completed between 9 and 220 13 weeks of gestation. Model performance was markedly better in participants with reference GA 221 ascertained inside compared to outside the recommended window. For example, Model 2 had an overall 222 MAE of 1.04 weeks among infants with reference GA between 9 and 13 weeks, compared to MAEs of 1.48 223 (<9 weeks), 1.34 (14-20 weeks) and 1.43 (>20 weeks) weeks for those with dating ultrasounds earlier and 224 later than the recommended window. A similar pattern was seen for Model 1 and Model 2 in heel and cord 225 samples both overall and in preterm and SGA newborns. Our study highlights the challenges in reliably 226 estimating GA in low resource settings, even in those with access to dating ultrasound, given that the timing of dating ultrasound is critical to accurate estimations of GA.^{3,18} Indeed, most pregnant women in Kenya 227 228 access ANC for the first time in the second trimester¹⁹. These challenges further underscore the need for 229 novel, reliable GA estimation methods that can be adopted in LMICs.

230

231 Given the significant barriers to obtaining an early dating ultrasound, the metabolic GA approach may be a 232 more feasible and accurate approach to GA dating than dating ultrasound when the timing of the latter is 233 variable. Our study also demonstrated the utility of cord blood samples, which could further strengthen the 234 feasibility of our approach in low resource settings. Cord blood samples are obtained shortly after birth and 235 remove the burden of sample collection before discharge, do not cause any discomfort to the newborn and 236 may be more readily accepted by parents who are not accustomed to the heel prick procedure. Given the 237 higher prevalence of HIV in our patient population, our results also provide reassurance that HIV positive 238 status does not appear to impact performance of algorithms based only on clinical measurements (Model 1) 239 or those including metabolic markers measured in heel prick or cord blood (Model 2).

240

The major limitation of our study was the small number of GA ultrasounds conducted during the optimal reference time-period. Therefore, a gold standard for reliable comparison with accurate true GA was not possible for a large percentage of the sample. Strengths of the study include the real-world approach to evaluating the algorithm, allowing us to assess not only model performance but the feasibility of this GA estimation approach as well.

246

Our study demonstrated that, despite being conducted within a prospective pregnancy cohort with a welldefined protocol in a controlled research setting, there were still challenges in obtaining a true reference GA measurement. The results of this evaluation suggest that postnatal GA estimation algorithms such as the ones we have developed are both feasible and accurate, and previous analyses have indicated that GA estimation algorithm approaches are also potentially cost-effective.²⁰ Therefore, we believe that GA estimation algorithms based on metabolic analysis of heel prick or cord blood DBS may be able to serve an important role in both individual infant estimates of GA and population level estimations of preterm birth rates.

254 Algorithm-based GA estimates have potential even in settings where early ultrasound is available, given the

substantial heterogeneity in timing of reference GA ultrasound in our population, a factor that may

compromise the accuracy of estimates based on ultrasound alone. Given these findings, we believe that GA

estimation algorithms may serve an important role in providing both individual estimates of GA and

- 258 population-level estimates of preterm birth.
- 259 260

261 Acknowledgements

262 This research was supported by the Bill & Melinda Gates Foundation (OHRI: OPP1184574; Stanford:

263 OPP1182996).

264 Contributions

- 265 Conceptualization KW, GLD, VW, PC, NO; Data Curation BON, RA, ABB, RD, ML; Formal Analysis SH;
- 266 Funding Acquisition KW, GLD, VW; Investigation NO, SM, BON, RA, ABB, LM, LAW; Methodology
- 267 VW, KW, GLD, PC, ML, LAW; Project Administration ABB, ML, LM, VW, NO, RA; Resources NO, LM,
- 268 ML, VW, RA BON; Software SH; Supervision KW, GLD, VW, NO; Writing -original Draft preparation-
- ABB, SH, RD; Writing-review and editing- all authors reviewed and edited the manuscript.
- 270 271

272 **References**

- World Health Organization. *Born Too Soon: The Global Action Report on Preterm Birth.*;
 2012. doi:http://whqlibdoc.who.int/publications/2012/9789241503433_eng.pdf
- 275 2. Blencowe H, Cousens S, Chou D, et al. Born Too Soon : The global epidemiology of 15
 276 million preterm births Understanding the data Preterm birth -- what is it ? Defining preterm
 277 birth. 2013;10(Suppl 1):1-13. doi:10.1186/1742
- 5. Hoffman CS, Messer LC, Mendola P, Savitz DA, Herring AH, Hartmann KE. Comparison of gestational age at birth based on last menstrual period and ultrasound during the first

- trimester. *Paediatr Perinat Epidemiol*. 2008;22(6):587-596. doi:10.1111/j.1365 3016.2008.00965.x
- 19. Nyiro JU, Bukusi E, Mwaengo D, et al. Implications of gestational age at antenatal care
 attendance on the successful implementation of a maternal respiratory syncytial virus (RSV)
 vaccine program in coastal Kenya. *BMC Public Health*. 2020;20(1). doi:10.1186/S12889020-09841-9
- 286 20. Coyle K, Quan AML, Wilson LA, et al. Cost-effectiveness of a gestational age metabolic
 287 algorithm for preterm and small-for-gestational-age classification. *Am J Obstet Gynecol* 288 *MFM*. 2021;3(1):100279. doi:10.1016/j.ajogmf.2020.100279
- 289
- 290

2	n	1
Z	Э	т

	Canada n=39, 666 (Ontario test cohort)	Kenya Heel Prick n=1,039	Kenya Cord Blood n=1,012
Sex, n(%)			
Male	19,536 (49.3%)	526 (50.6%)	511 (50.5%)
Female	20,130 (50.5%)	513 (49.4%)	501 (49.5%)
Birth weight (g), mean ± SD			
Overall	3,379 ± 530.2	3,238.4 ± 468.9	3,238.5 ±470.1
Term infants only	3,430.6 ± 476.1	3,277.1 ± 430.6	3,274.6 ± 435.1
Preterm infants only	2,504.1 ± 622.8	2,840.0 ± 635.4	2869.0 ± 632.5
Low birth weight (<2500 g), n (%)	1,812 (4.6%)	48 (4.6%)	46 (4.6%)
SGA (<10th Centile), n (%)	1,561 (3.94%)	88 (8.5%)	87 (8.6%)
SGA (<3rd Centile), n (%)	363 (0.92%)	28 (2.7%)	30 (3.0%)
Completed gestational age wks, mean ± SD	39.3±1.6	39.1 ±1.9	39.1±1.9
Term (≥37 wks), n (%)	37,440 (94.4%)	947 (91.1%)	922 (91.1%)
Late Preterm (32-36 wks), n (%)	2,049 (5.2%)	88 (8.5%)	86 (8.5%)
Very Preterm (28-31 wks), n (%)	126 (0.3%)	4 (0.4%)	4 (0.4%)
Extremely Preterm (<28 wks), n (%)	51 (0.1%)	0	0

292 Table 2. Cohort Characteristics

293 SGA, small for gestational age (lowest 10 and 3 centiles within gestational age and sex strata,

calculated in the Ontario cohort using Intergrowth-21 centiles and applied uniformly in the Ontario,China and Philippines cohorts)

296 297

Table 3.	Summary	of model	performance to	estimate	gestational	age in	samples	from
Kenya								

Models	Kenya Heel Prick Samples			Kenya Cord Blood Samples		
	Overall, N=1,039	Preterm, N=93	SGA, N=88	Overall, N=1,012	Preterm, N=91	SGA, N=87
Model 1: Sex a	nd birth weight					
MAE (CI) RMSE (CI) % +/-1 wk (CI)	1.50 (1.41, 1.58) 2.02 (1.91, 2.13) 58.5 (55.3, 61.6)	2.64 (2.30, 3.01) 3.09 (2.75, 3.45) 24.1 (14.5, 34.1)	3.13 (2.85, 3.38) 3.39 (3.06, 3.70) 3.4 (0.0, 7.7)	1.51 (1.42, 1.59) 2.04 (1.94, 2.16) 58.4 (55.4, 61.6)	2.70 (2.39, 3.04) 3.14 (2.84, 3.49) 23.4 (13.7, 32.0)	3.17 (2.91, 3.46) 3.43 (3.10, 3.77) 3.6 (0.0, 8.3)
Model 2: Sex, Birth weight and analytes						
MAE (CI) RMSE (CI) % +/-1 wk (CI)	1.35 (1.27, 1.43) 1.83 (1.72, 1.94) 64.1 (61.1, 67.2)	2.62 (2.28, 2.99) 3.09 (2.74, 3.48) 29.4 (20.2, 38.9)	1.81 (1.57, 2.07) 2.18 (1.91, 2.46) 46.9 (35.8, 57.3)	1.44 (1.36, 1.53) 1.95 (1.85, 2.06) 61.2 (58.3, 63.9)	2.79 (2.46, 3.12) 3.19 (2.85, 3.57) 21.1 (11.8, 29.3)	2.06 (1.76, 2.36) 2.41 (2.13, 2.69) 33.2 (23.0, 44.6)

MAE: Mean absolute error; RMSE: Root mean square error; SGA: small for gestational age Data are presented as the mean and 2.5th and 97.5th bootstrap percentiles for MAE, RMSE and the percentage of model estimates within 1 and 2 weeks of ultrasound GA for 1000 bootstrap samples generated from each cohort.

Table 4. Summary of model performance to estimate gestational age in heel prick samples according to HIV status and timing of GA dating ultrasound

	Kenya Heel Prick Samples							
	HIV Neg, N=842	HIV Pos, N=197	US <9 weeks, N=28	US 9-13 weeks, N=120	US 14-20 weeks, N=503	US >20 weeks, N=386		
Model 1: Sex,	Model 1: Sex, birthweight multiple birth							
MAE (CI) RMSE (CI) % +/-1 wk (CI)	1.49 (1.39, 1.57) 2.01 (1.89, 2.13) 58.1 (54.8, 61.7)	1.56 (1.37 1.74) 2.06 (1.81, 2.31) 60.4 (53.9, 67.0)	1.51 (1.11, 1.93) 1.89 (1.53, 2.29) 49.6 (32.1, 67.7)	1.27 (1.08, 1.45) 1.61 (1.40, 1.83) 68.6 (60.2, 76.3)	1.57 (1.45, 1.69) 2.07 (1.92, 2.23) 55.5 (51.0, 60.0)	1.48 (1.33, 1.64) 2.08 (1.89, 2.28) 60.0 (54.6, 65.0)		
Model 2: Sex, birthweight multiple birth and analytes								
MAE (CI) RMSE (CI) % +/-1 wk (CI)	1.34 (1.27, 1.43) 1.81 (1.70, 1.93) 63.7 (60.5, 66.9)	1.35 (1.16, 1.53) 1.93 (1.67, 2.20) 65.7 (59.5, 72.0)	1.48 (1.09, 1.90) 1.85 (1.46, 2.23) 49.6 (29.6, 66.7)	1.04 (0.87, 1.22) 1.38 (1.19, 1.58) 71.5 (63.3, 79.1)	1.34 (1.23, 1.46) 1.84 (1.68, 2.00) 64.5 (59.8, 68.9)	1.43 (1.31, 1.58) 1.94 (1.77, 2.13) 62.2 (56.8, 66.8)		

MAE: Mean absolute error; RMSE: Root mean square error; SGA: small for gestational age Data are presented as the mean and 2.5th and 97.5th bootstrap percentiles for MAE, RMSE and the percentage of model estimates within 1 and 2 weeks of ultrasound GA for 1000 bootstrap samples generated from each cohort.

Table 5. Summary of model performance in Cord Blood Samples According to HIV Status and Timing of GA Dating Ultrasound (US)

Models	HIV Neg, N=822	HIV Pos, N=190	US <9 weeks, N=27	US 9-13 weeks, N=121	US 14-20 weeks, N=494	US >20 weeks, N=370
Model 1: Sex, birthweight and multiple birth						
MAE (CI) RMSE (CI) % +/-1 wk (CI)	1.49 (1.41, 1.59) 2.03 (1.92, 2.15) 57.9 (54.3, 60.9)	1.56 (1.37, 1.76) 2.08 (1.86, 2.34) 60.5 (53.3, 67.0)	1.41 (0.96, 1.89) 1.84 (1.43, 2.26) 55.6 (35.7, 73.9)	1.28 (1.10, 1.45) 1.63 (1.39, 1.84) 67.5 (59.2, 76.0)	1.58 (1.46, 1.71) 2.10 (1.94, 2.25) 55.0 (50.8, 59.4)	1.48 (1.33, 1.63) 2.09 (1.88, 2.27) 60.1 (54.7, 64.6)
Model 2: Sex, birthweight, multiple birth, and analytes						
MAE (CI) RMSE (CI) % +/-1 wk (CI)	1.43 (1.34, 1.52) 1.92 (1.81, 2.04) 61.4 (58.3, 64.4)	1.49 (1.29, 1.70) 2.04 (1.80, 2.28) 60.4 (53.1, 67.6)	1.60 (1.22, 2.03) 1.89 (1.49, 2.30) 55.4 (36.7, 73.1)	1.08 (0.90, 1.27) 1.44 (1.25, 1.62) 70.5 (62.2, 78.2)	1.46 (1.33, 1.57) 1.99 (1.83, 2.14) 61.7 (57.5, 65.7)	1.53 (1.39, 1.66) 2.03 (1.87, 2.19) 57.9 (53.3, 62.6)

MAE: Mean absolute error; RMSE: Root mean square error; SGA: small for gestational age Data are presented as the mean and 2.5th and 97.5th bootstrap percentiles for MAE, RMSE and the percentage of model estimates within 1 and 2 weeks of ultrasound GA for 1000 bootstrap samples generated from each cohort.

Table 6. Summary of model performance in heel and cord blood samples restricted to 9-	-13
week ultrasound.	

Models	Kenya Heel Prick Samples			Kei	nya Cord Blood Sa	mples		
	Overall, N=120	Preterm, N=5	SGA, N=13	Overall, N=120	Preterm, N=5	SGA, N=14		
Model 1: Sex,	Model 1: Sex, birthweight and multiple birth							
MAE (CI) RMSE (CI) % +/-1 wk (CI)	1.27 (1.08, 1.45) 1.61 (1.40, 1.83) 68.6 (60.2, 76.3)	2.80 (1.00, 4.50) 3.19 (1.41, 4.53) 18.8 (0.0, 60.0)	2.47 (1.92, 3.00) 2.63 (2.02, 3.22) 7.8 (0.0, 27.3)	1.27 (1.08, 1.47) 1.62 (1.39, 1.87) 67.6 (59.2, 76.7)	2.82 (1.20, 4.33) 3.22 (1.73, 4.43) 19.6 (0.0, 66.7)	2.52 (2.08, 3.00) 2.67 (2.17, 3.22) 7.5 (0.0, 25.0)		
Model 2: Sex,	Model 2: Sex, birthweight, multiple birth and analytes							
MAE (CI) RMSE (CI) % +/-1 wk (CI)	1.04 (0.87, 1.22) 1.38 (1.19, 1.58) 71.5 (63.3, 79.1)	2.56 (1.50, 4.00) 2.78 (1.58, 4.00) 18.8 (0.0, 60.0)	1.07 (0.46, 1.70) 1.44 (0.73, 2.02) 77.0 (50.0, 100.0)	1.07 (0.88, 1.23) 1.43 (1.24, 1.62) 71.0 (62.5, 79.2)	2.60 (1.00, 4.00) 2.94 (1.63, 4.00) 19.6 (0.0, 66.7)	1.52 (0.88, 2.15) 1.90 (1.30, 2.37) 49.4 (22.2, 75.0)		

MAE: Mean absolute error; RMSE: Root mean square error; SGA: small for gestational age Data are presented as the mean and 2.5th and 97.5th bootstrap percentiles for MAE, RMSE and the percentage of model estimates within 1 and 2 weeks of ultrasound GA for 1000 bootstrap samples generated from each cohort.